NewsCanada
A bidding war is under way for a Canadian cannabis producer based in Edmonton. Between 3 and 5 November 2026, Curaleaf kept its improved offer, while the target agreed to a rival Organigram proposal worth about $561 million.
Key points
- Curaleaf maintained its improved October 2026 offer for the Edmonton-based producer.
- The target accepted Organigram's alternative offer, valued at about 1 million, at .80 per share.
- The outcome is not settled: the board could still back a higher Curaleaf bid or confirm the Organigram deal.
CBD Hash at Spliff · from €3.50/g · ★ 4.9/5 (425 reviews)
72 h delivery in Europe · Free delivery from €99
The Curaleaf Organigram bidding war centres on Aurora Cannabis, a Canadian producer that once ran a large greenhouse near Edmonton’s international airport. According to MarketScreener, Curaleaf has maintained the improved offer it made in October 2026.
Aurora backs the Organigram proposal
Aurora has accepted an alternative offer from Organigram, reported the Edmonton Journal. The deal is valued at about $561 million in total.
Organigram is offering $7.80 per share to Aurora shareholders. The newspaper also reported that the cash portion is capped at $253.6 million.
Access to due diligence differs
Per MarketScreener, Aurora gave Organigram access to due diligence but did not give the same access to Curaleaf. That detail frames the dispute between the two bidders.
The companies are based in different places: Curaleaf in Connecticut, Organigram in New Brunswick and Aurora in Edmonton.
What the market price shows
Aurora shares closed at $7.24 on the TSX on Wednesday 4 November 2026, according to the Edmonton Journal. That is below the $7.80 per share offered by Organigram.
The cash cap leaves one point open. It is not yet known whether some shareholders who ask for cash would receive shares instead.
From legalisation boom to consolidation
Aurora was once a major Canadian player. Growth expectations after the legalisation of recreational cannabis in Canada in autumn 2018 were not met, the Edmonton Journal noted.
The company closed its massive greenhouse near Edmonton in spring 2022, following heavy net losses and weak sales.
Aurora’s chief on the logic of the deal
Miguel Martin, Aurora’s executive chairman and CEO, said the combination would pair Aurora’s strength in international medical cannabis with Organigram’s lead in Canadian recreational cannabis, according to the Edmonton Journal. He also pointed to potential for international and global growth.
What happens next
The final outcome is undecided. Aurora’s board could accept a higher Curaleaf bid or confirm the agreement with Organigram.
Ce que ça change pour toi
For a European reader, this is a Canadian corporate story with no direct effect on the rules or availability of products in Europe. It may hint at consolidation among large licensed producers, but that would remain a reading of the market, not a fact from the sources.
If you want to see what is sold in Europe, browse our CBD flower collection or the full product range. Every Spliff product is lab-tested: THC content below 0.3% (0% for vapes and pods).
FAQ
What happened in the Curaleaf Organigram bidding war?
Curaleaf kept its improved October 2026 offer, while Aurora accepted Organigram's alternative proposal, valued at about $561 million. The final result is not yet decided.
What price does Organigram offer per share?
Organigram offers $7.80 per share, with the cash portion capped at $253.6 million, according to the Edmonton Journal. Aurora closed at $7.24 on the TSX on 4 November 2026.
Could the Aurora stock price change after this news?
The sources give no forecast. The board could still back a higher Curaleaf bid or confirm the Organigram deal, so the outcome remains open.
Sources
- MarketScreener — Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis
- Edmonton Journal — Edmonton's Aurora Cannabis agrees to sell to Organigram, eight years after the legalization boom
Image created with AI
